Genmab A/S Stock Nasdaq
Stocks
GMAB
US3723032062
Biotechnology & Medical Research
OTC Markets Traded|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 28.52 USD | +3.17% |
|
+9.17% | -7.42% |
| 07-03 | Nordic stocks in North America, Ericsson fell 1.6% | FW |
| 07-01 | Nordic stocks in North America, AstraZeneca rose 1.3% | FW |
| Market Cap | 115B 17.56B 15.35B 14.11B 13.15B 24.94B 1,672B 25.32B 169B 65.83B 822B 65.91B 64.49B 2,832B | P/E 2026 * |
24.5x | P/E 2027 * | 17.2x |
|---|---|---|---|---|---|
| Enterprise Value | 134B 20.55B 17.96B 16.51B 15.39B 29.18B 1,956B 29.63B 198B 77.04B 962B 77.12B 75.47B 3,314B | EV / Sales 2026 * |
4.84x | EV / Sales 2027 * | 3.92x |
| Free-Float |
95.41% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Genmab A/S
| 1 day | +3.17% | ||
| 1 week | +9.17% | ||
| Current month | +3.80% | ||
| 1 month | +19.41% | ||
| 3 months | +3.69% | ||
| 6 months | -10.39% | ||
| Current year | -7.42% |
| 1 week | 25.97 |  | 28.78 |
| 1 month | 24.08 | | 28.78 |
| Current year | 23.62 | | 35.43 |
| 1 year | 20.33 | | 35.43 |
| 3 years | 17.24 | | 42.72 |
| 5 years | 17.24 | | 49.07 |
| 10 years | 12.1 | | 49.07 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 65 | 2010-05-31 | |
Anthony Pagano
DFI | Director of Finance/CFO | 48 | 2020-02-29 |
Rayne Waller
CTO | Chief Tech/Sci/R&D Officer | - | 2024-08-15 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 75 | 2003-10-31 | |
| Director/Board Member | 58 | 2014-12-31 | |
| Director/Board Member | 75 | 2014-12-31 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +3.17% | +9.17% | - | - | 17.61B | |
| +0.68% | +5.92% | +80.45% | +137.78% | 58.73B | |
| +2.32% | +5.03% | +75.51% | +94.88% | 53.92B | |
| +3.86% | +6.93% | -11.32% | -9.53% | 24.67B | |
| +4.30% | +7.95% | +14.11% | +437.83% | 24.19B | |
| +4.74% | +13.68% | +45.58% | -1.42% | 18.8B | |
| 0.00% | +20.78% | +178.93% | +360.74% | 16.25B | |
| +3.50% | +1.97% | +21.02% | +191.95% | 14.04B | |
| +6.72% | +19.38% | +42.82% | - | 13.9B | |
| +2.67% | +3.01% | +76.70% | +133.90% | 12.18B | |
| Average | +3.20% | +6.52% | +58.20% | +168.27% | 26.3B | |
| Weighted average by Cap. | +2.69% | +5.23% | +61.04% | +151.39% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 27.73B 4.24B 3.71B 3.41B 3.18B 6.03B 404B 6.12B 40.94B 15.92B 199B 15.93B 15.59B 685B | 32.45B 4.97B 4.34B 3.99B 3.72B 7.06B 473B 7.16B 47.91B 18.62B 232B 18.65B 18.25B 801B |
| Net income | 4.76B 729M 637M 586M 546M 1.04B 69.41B 1.05B 7.03B 2.73B 34.12B 2.74B 2.68B 118B | 7.03B 1.08B 941M 864M 806M 1.53B 102B 1.55B 10.38B 4.03B 50.36B 4.04B 3.95B 174B |
| Net Debt | 19.52B 2.99B 2.61B 2.4B 2.24B 4.24B 285B 4.31B 28.82B 11.2B 140B 11.22B 10.98B 482B | 12.49B 1.91B 1.67B 1.54B 1.43B 2.71B 182B 2.76B 18.43B 7.17B 89.45B 7.17B 7.02B 308B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-07-02 | US$28.52 | +3.17% | 1,414,977 |
| 26-07-01 | US$27.64 | +0.62% | 1,450,434 |
| 26-06-30 | US$27.47 | +5.57% | 2,573,567 |
| 26-06-29 | US$26.02 | -0.38% | 2,029,457 |
| 26-06-26 | US$26.12 | -0.08% | 1,778,429 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- GMAB Stock
- GMAB Stock
Select your edition
All financial news and data tailored to specific country editions
